Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Drug Makers Eschew Flu Vaccines In Favor Of Treatment

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers continue turning out flu treatments while their European counterparts concentrate on vaccines to prevent the diseases. Academic institutions are more likely to lead production of vaccines in Japan, with the exception of Denka Seiken, possibly hampering the country's ability to respond to a need for a sudden production increase. Major domestic drug makers in Japan have been reluctant to produce flu vaccines, possibly because they see few profits in doing so, as opposed to higher risks of side effects from the products. (Click here for more - a subscription may be required

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel